Kiniksa Pharmaceuticals International (KNSA) Announces Q1 2026 Financial Results

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) is one of the best drug stocks to buy according to analysts. Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced its fiscal Q1 2026 financial results on April 28 and also provided updates regarding its recent portfolio execution. The company reported that net product revenue for ARCALYST® in fiscal Q1 2026 reached $214.3 million, representing 56% year-over-year growth. The company experienced growth in both new and repeat prescribers as fiscal Q1 progressed, which offered momentum for its ARCALYST franchise for the rest of the year. Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) thus raised its 2026 ARCALYST net sales guidance to between $930 and $945 million from between $900 and $920 million. Total revenue for fiscal Q1 rose to $214.3 million, compared to $137.8 million for the first quarter of 2025.

The company further reported that the KPL-387 Phase 2 recurrent pericarditis data is expected in the second half of 2026, with the Phase 3 pivotal trial expected to initiate by the end of the year. In addition, management stated that the fiscal Q1 2026 cash balance grew to $468.1 million.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) is a commercial-stage biopharmaceutical company that discovers, acquires, develops, and commercializes therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs.

While we acknowledge the risk and potential of KNSA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than KNSA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.